148 related articles for article (PubMed ID: 12431607)
1. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Itagaki F; Homma M; Yuzawa K; Fukao K; Kohda Y
Transplant Proc; 2002 Nov; 34(7):2777-8. PubMed ID: 12431607
[No Abstract] [Full Text] [Related]
2. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Homma M; Itagaki F; Yuzawa K; Fukao K; Kohda Y
Transplantation; 2002 Jan; 73(2):303-4. PubMed ID: 11821750
[No Abstract] [Full Text] [Related]
3. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
4. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Miura M; Kagaya H; Tada H; Sagae Y; Satoh S; Habuchi T; Suzuki T
Xenobiotica; 2005 May; 35(5):479-86. PubMed ID: 16012079
[TBL] [Abstract][Full Text] [Related]
5. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
6. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
8. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
[TBL] [Abstract][Full Text] [Related]
9. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
Takahashi K; Yano I; Fukuhara Y; Katsura T; Takahashi T; Ito N; Yamamoto S; Ogawa O; Inui K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):441-4. PubMed ID: 18159131
[TBL] [Abstract][Full Text] [Related]
10. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
11. [Cause and prevention of nocturnal gastric acid breakthrough].
Adachi K; Kinoshita Y
Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
[No Abstract] [Full Text] [Related]
12. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
13. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
Hosohata K; Masuda S; Katsura T; Takada Y; Kaido T; Ogura Y; Oike F; Egawa H; Uemoto S; Inui K
Drug Metab Dispos; 2009 Apr; 37(4):821-6. PubMed ID: 19139162
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
15. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
16. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
17. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
18. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
19. [Investigation about 3rd line eradication of H. pylori].
Nakagawa S; Kato M; Shimizu Y; Nakagawa M; Asaka M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():466-9. PubMed ID: 16363580
[No Abstract] [Full Text] [Related]
20. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
